Abstract: This application provides a bead with a covalently attached chemical compound and a covalently attached DNA barcode and methods for using such beads. The bead has many substantially identical copies of the chemical compound and many substantially identical copies of the DNA barcode. The compound consists of one or more chemical monomers, where the DNA barcode takes the form of barcode modules, where each module corresponds to and allows identification of a corresponding chemical monomer. The nucleic acid barcode can have a concatenated structure or an orthogonal structure. Provided are method for sequencing the bead-bound nucleic acid barcode, for cleaving the compound from the bead, and for assessing biological activity of the released compound.
Type:
Grant
Filed:
May 8, 2020
Date of Patent:
April 20, 2021
Assignee:
Plexium, Inc.
Inventors:
Kandaswamy Vijayan, Andrew Boyd MacConnell, Joseph Franklin Rokicki, Michael Van Nguyen
Abstract: Methods, compositions and kits are provided herein for insertional modification of nucleic acids by, for example transposase-mediated covalent insertion of insertion sequence into a sample nucleic acid molecule. Using sequence of the insertion to direct amplification of adjacent nucleic acid sequence, and using bar codes to map amplified sequence to partitions, one can map sample nucleic acid sequence to single molecules of the nucleic acid sample that are derived directly from the sample nucleic acid molecule.
Type:
Grant
Filed:
February 25, 2016
Date of Patent:
April 6, 2021
Assignees:
JUMPCODE GENOMICS, INC., THE SCRIPPS RESEARCH INSTITUTE
Inventors:
Keith Brown, Daniel R. Salomon, Steven Head, Azeem Siddique, Phillip Ordoukhanian
Abstract: Embodiments provided herein relate to methods and compositions for next generation sequencing. Some embodiments include the preparation of a template library from a target nucleic acid using one-sided transposition, sequencing the template library, and capturing the contiguity information.
Type:
Grant
Filed:
January 7, 2020
Date of Patent:
April 6, 2021
Assignee:
Illumina, Inc.
Inventors:
Frank J. Steemers, Jeffrey S. Fisher, Kevin L. Gunderson, Sasan Amini, Christian Gloeckner
Abstract: The invention provides cyclosporin A analogues that are NTCP inhibitors and useful for treating HBV and/or HDV infection(s), hepatoprotection and amelioration of hypercholesterolemia, diabetes and inhibiting cancer.
Type:
Grant
Filed:
October 12, 2020
Date of Patent:
March 30, 2021
Assignee:
National Institute of Biological Sciences, Beijing
Abstract: The use of an emulsion for protecting the skin against aggressive chemical agents, wherein this emulsion includes at least one amphoteric chelating agent which includes a complex based on aluminium and on ethylenediaminetetraacetic acid or the trisodium salt thereof, having the general formula [Al(Y)Bn]c?Dc with B being OH?, BO2? or H+, Y being a tetracarboxylate which can be protonated four times to form ethylenediaminetetraacetic acid, n being an integer equal to 0, 1, 2 or 3, D being a counterion, preferably Na+, c being an integer equal to 0, 1, 2 or 3 and c? being a relative number having the same absolute value as c.
Type:
Grant
Filed:
July 17, 2013
Date of Patent:
March 23, 2021
Assignee:
PREVOR INTERNATIONAL
Inventors:
Joel Blomet, Laurence Mathieu, Marie-Claude Meyer
Abstract: This application provides a bead with a covalently attached chemical compound and a covalently attached DNA barcode and methods for using such beads. The bead has many substantially identical copies of the chemical compound and many substantially identical copies of the DNA barcode. The compound consists of one or more chemical monomers, where the DNA barcode takes the form of barcode modules, where each module corresponds to and allows identification of a corresponding chemical monomer. The nucleic acid barcode can have a concatenated structure or an orthogonal structure. Provided are method for sequencing the bead-bound nucleic acid barcode, for cleaving the compound from the bead, and for assessing biological activity of the released compound.
Type:
Grant
Filed:
August 7, 2019
Date of Patent:
March 16, 2021
Assignee:
Plexium, Inc.
Inventors:
Kandaswamy Vijayan, Andrew Boyd MacConnell, Joseph Franklin Rokicki
Abstract: In one embodiment, a polyethoxylated alcohol sulfate composition is provided which includes a polyethoxylated alcohol sulfate, such as sodium laureth ether sulfate (SLES), water, a mono-alcohol, and a polyol. The two alcohols form a synergistic blend, enabling a significant reduction of the viscosity of the polyethoxylated alcohol sulfate composition. Also provided is an embodiment of a method for modifying the rheology of polyethoxylated alcohol sulfate by use of a mono-alcohol and a polyol simultaneously. Finally provided is an embodiment of a detergent composition which is prepared by use of the polyethoxylated alcohol sulfate composition described herein, in addition to other commonly known ingredients.
Type:
Grant
Filed:
December 5, 2017
Date of Patent:
March 2, 2021
Assignee:
Henkel IP & Holding GmbH
Inventors:
Daniel Thomas Piorkowski, David S. Stott, II
Abstract: The present invention relates to a method of identifying nucleic acid regions within a nucleic acid sample which interact with one another. In particular, the method relates to a chromatin conformation capture (3C) method which may be used to analyse the interactions between enhancers, silencers, boundary elements and promoters at individual loci at high resolution.
Abstract: Methods for the treatment of spinal cord injury or traumatic brain injury are provided. In certain embodiments, the methods include the use of a molecular tweezers and/or nucleobase oligomer capable of inhibiting the accumulation or aggregation of one or more amyloidogenic proteins and/or synuclein proteins. Examples of treatments that may inhibit accumulation or aggregation of one or more amyloidogenic proteins and/or synuclein proteins include treatment with a synuclein antisense nucleobase oligomer or treatment with the molecular tweezers CLR01. These treatments may improve outcomes of spinal cord surgery or traumatic brain injury, including, without limitation, neuronal survival, neuronal regeneration, and recovery of neuronal functions.
Type:
Grant
Filed:
November 7, 2014
Date of Patent:
February 16, 2021
Assignees:
The Regents of the University of California, The Marine Biological Laboratory, Board of Regents, The University of Texas System
Inventors:
Jennifer R. Morgan, Gal Bitan, David J. Busch
Abstract: Aspects of the invention relate to methods for preparing and analyzing a sequencing library from a mixed cell-free DNA (cfDNA) sample, wherein the mixed sample includes double-stranded DNA (dsDNA), damaged dsDNA (e.g., nicked dsDNA), and single-stranded DNA (ssDNA) molecules. The subject methods facilitate the collection of information from dsDNA, ssDNA and damaged DNA (e.g., nicked DNA) molecules in a sample, thereby providing enhanced diagnostic information as compared to sequencing libraries that are prepared from dsDNA alone.
Type:
Grant
Filed:
October 24, 2019
Date of Patent:
February 2, 2021
Assignee:
GRAIL, Inc.
Inventors:
Matthew H. Larson, Hyunsung John Kim, Nick Eattock, Xiao Yang
Abstract: Provided herein are lipidic furan, pyrrole, and thiophene compounds, compositions, and methods using such compounds and compositions for the treatment of atrophic vaginitis. Specifically, the invention includes administering an effective amount of a compound of Formula I, I?, or I?, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from atrophic vaginitis.
Abstract: A method for identifying interactions of DNA, RNA, and/or protein molecules in a cell includes distributing a cell lysate or fraction thereof into a plurality of lysate suspensions, adding a unique nucleotide tag to each lysate suspension to tag each DNA, RNA, and/or protein, pooling the tagged suspensions, and repeating the tagging, pooling, and sorting (distributing) as desired to decrease the probability that non-interacting molecules will receive all of the same nucleotide tags.
Abstract: Provided in the present invention is a method for constructing a high-resolution single cell Hi-C library with a large amount of information, comprising the following steps: Step B: obtain a small amount of fixed chromatin; Step C: digest the fixed chromatin in Step B to obtain fragments of the fixed chromatin; Step D: reconnect the fragments of the fixed chromatin in Step C directly to obtain reconnected fragments of the fixed chromatin; Step E: de-fix the reconnected fragments of the fixed chromatin in Step D to release DNA fragments; Step F: amplify the released DNA fragments in Step E to obtain amplified products; and Step H: construct a sequencing DNA library by using the amplified products as the DNA fragments to be sequenced.
Abstract: Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.
Type:
Grant
Filed:
November 13, 2015
Date of Patent:
January 26, 2021
Assignee:
UNIVERSITY OF WASHINGTON
Inventors:
Georg Seelig, Richard Muscat, Alexander B. Rosenberg
Abstract: The problems to be solved by the present invention are to provide a novel FGFR inhibitor that is potent and highly selective, and to provide an antitumor agent with which side effects such as an elevated blood phosphorus concentration are alleviated while maintaining the antitumor effect of the FGFR inhibitor. The present invention provides an antitumor agent comprising a 3,5-di-substituted benzene alkynyl compound represented by general formula (I) or salt thereof, which is used by administering the 3,5-di-substituted benzene alkynyl compound or salt thereof according to an administration schedule of two or more times/week at an administration interval of at least one day between doses.
Abstract: The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.
Abstract: Interaction with a protein is detected by using an RNA probe containing the following sequences; (i) a complementary strand sequence to a DNA barcode sequence, (ii) a sequence of a first stem portion, (iii) a sequence of a second stem portion complementary to the first stem portion for hybridizing with the first stem portion to form a double-stranded stem, and (iv) a sequence of a loop portion contained in RNA for linking the first and second stem portions.
Abstract: The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. Also provided are methods for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor and methods for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor.
Type:
Grant
Filed:
October 30, 2017
Date of Patent:
January 5, 2021
Assignee:
BIOMED VALLEY DISCOVERIES, INC.
Inventors:
Saurabh Saha, Dean Welsch, Gary DeCrescenzo, Jeffrey James Roix
Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.
Type:
Grant
Filed:
May 10, 2019
Date of Patent:
January 5, 2021
Assignee:
ONO PHARMACEUTICAL CO., LTD.
Inventors:
Akira Imagawa, Takashi Kondo, Taihei Nishiyama, Steve Courtney, Chris Yarnold, Osamu Ichihara, Stuart Flanagan